EVOLENT HEALTH,INC CLASS A COM Barclays PLC holding in Form 13-F
Barclays PLC reported holding of EVH
This chart displays the historical ownership data of EVH by Barclays PLC. At the end of Q2 2016 the holding was valued at $144,000. This increased to $10,262,000 at the end of Q1 2025.
| Date | Holding Value |
|---|---|
| 144000 | |
| 970000 | |
| 1757000 | |
| 934000 | |
| 479000 | |
| 0 | |
| 679000 | |
| 22000 | |
| 942000 | |
| 1636000 | |
| 2259000 | |
| 3000 | |
| 3718000 | |
| 1217000 | |
| 0 | |
| 359000 | |
| 972000 | |
| 871000 | |
| 674000 | |
| 2012000 | |
| 430000 | |
| 631000 | |
| 675000 | |
| 1592000 | |
| 527000 | |
| 1868000 | |
| 3437000 | |
| 1213000 | |
| 796000 | |
| 1278000 | |
| 2642000 | |
| 2236000 | |
| 3039000 | |
| 3539000 | |
| 8498000 | |
| 4905000 | |
| 1861000 | |
| 10298000 | |
| 10262000 |
About EVOLENT HEALTH INC CLASS A COM
Evolent Health provides value-based care management solutions focusing on complex conditions like cancer, cardiovascular disease, and musculoskeletal issues. The company operates in the healthcare industry, partnering with health plans and risk-bearing entities to enhance care delivery through evidence-based clinical pathways. Evolent's primary offerings include specialty care management services, total cost of care management, and administrative services, utilizing its proprietary CarePro™ platform to support high-quality care delivery.
Evolent generates revenue through fixed fees per member per month, based on non-capitation and capitation arrangements, driven by the number of managed members and utilized services. Its client base primarily consists of payers and providers in the healthcare sector, with whom it maintains long-term partnerships. The company’s operational structure includes various acquisitions, such as New Century Health, Vital Decisions, IPG, and NIA, which have expanded its capabilities in specialty care management.
Key factors impacting Evolent's business performance include its ability to innovate and provide integrated solutions amidst competitive pressures, as well as its focus on performance-based contracts. The company's use of technology, like the Identifi® platform, enhances care delivery efficiency and positions it to meet the evolving needs of the value-based healthcare market.
Disclaimer
FilingExplorer.com is not affiliated with, endorsed by, or in any way officially connected with any of the securities, funds, or companies mentioned on this site. The information provided is sourced from publicly available datasets and is presented for informational purposes only. While we strive for accuracy, we do not guarantee the completeness, timeliness, or accuracy of any information on this site. Users should not rely solely on this information for making investment decisions and should always conduct their own research or consult with a qualified financial advisor. Security and company summaries are based on public data available in recent SEC filings, and may not be entirely accurate. The mention of any security does not constitute a recommendation to buy, sell, or hold that or any other security. FilingExplorer.com is not responsible for any investment decisions made based on the information provided on this site.
See our Terms of Service
Barclays PLC reported holdings of EVH from Q2 2016 to Q1 2025
| Reporting period | Holding Type | Market Value | % of portfolio | Shares | Change in shares | % Change in shares | Qtr end price |
|---|---|---|---|---|---|---|---|
| Q2 2016 | Stock | $144,000 | < 0.01% | 7,500 | 7,500 | 0 | $19.20 |
| Q3 2016 | Stock | $970,000 | < 0.01% | 39,406 | 31,906 | 425.41% | $24.62 |
| Q4 2016 | Stock | $1,757,000 | < 0.01% | 118,732 | 79,326 | 201.3% | $14.80 |
| Q1 2017 | Stock | $934,000 | < 0.01% | 41,850 | -76,882 | -64.75% | $22.32 |
| Q1 2017 | Call | $479,000 | < 0.01% | 21,500 | 21,500 | 0 | $22.28 |
| Q2 2017 | Call | $0 | 0 | 0 | -21,500 | -100.0% | - |
| Q2 2017 | Stock | $679,000 | < 0.01% | 26,760 | -15,090 | -36.06% | $25.37 |
| Q3 2017 | Stock | $22,000 | < 0.01% | 1,244 | -25,516 | -95.35% | $17.68 |
| Q4 2017 | Stock | $942,000 | < 0.01% | 76,615 | 75,371 | 6058.76% | $12.30 |
| Q1 2018 | Stock | $1,636,000 | < 0.01% | 114,766 | 38,151 | 49.8% | $14.26 |
| Q2 2018 | Stock | $2,259,000 | < 0.01% | 107,346 | -7,420 | -6.47% | $21.04 |
| Q3 2018 | Put | $3,000 | < 0.01% | 100 | 100 | 0 | $30.00 |
| Q3 2018 | Stock | $3,718,000 | < 0.01% | 130,913 | 23,567 | 21.95% | $28.40 |
| Q4 2018 | Stock | $1,217,000 | < 0.01% | 61,005 | -69,908 | -53.4% | $19.95 |
| Q4 2018 | Put | $0 | 0 | 0 | -100 | -100.0% | - |
| Q1 2019 | Stock | $359,000 | < 0.01% | 28,586 | -32,419 | -53.14% | $12.56 |
| Q2 2019 | Stock | $972,000 | < 0.01% | 122,450 | 93,864 | 328.36% | $7.94 |
| Q3 2019 | Stock | $871,000 | < 0.01% | 120,976 | -1,474 | -1.2% | $7.20 |
| Q4 2019 | Stock | $674,000 | < 0.01% | 74,576 | -46,400 | -38.35% | $9.04 |
| Q1 2020 | Stock | $2,012,000 | < 0.01% | 370,509 | 295,933 | 396.82% | $5.43 |
| Q2 2020 | Stock | $430,000 | < 0.01% | 60,341 | -310,168 | -83.71% | $7.13 |
| Q3 2020 | Stock | $631,000 | < 0.01% | 50,866 | -9,475 | -15.7% | $12.41 |
| Q4 2020 | Stock | $675,000 | < 0.01% | 42,172 | -8,694 | -17.09% | $16.01 |
| Q1 2021 | Stock | $1,592,000 | < 0.01% | 78,814 | 36,642 | 86.89% | $20.20 |
| Q2 2021 | Stock | $527,000 | < 0.01% | 24,954 | -53,860 | -68.34% | $21.12 |
| Q3 2021 | Stock | $1,868,000 | < 0.01% | 60,262 | 35,308 | 141.49% | $31.00 |
| Q4 2021 | Stock | $3,437,000 | < 0.01% | 124,229 | 63,967 | 106.15% | $27.67 |
| Q1 2022 | Stock | $1,213,000 | < 0.01% | 37,562 | -86,667 | -69.76% | $32.29 |
| Q2 2022 | Stock | $796,000 | < 0.01% | 25,931 | -11,631 | -30.96% | $30.70 |
| Q3 2022 | Stock | $1,278,000 | < 0.01% | 35,554 | 9,623 | 37.11% | $35.95 |
| Q4 2022 | Stock | $2,642,000 | < 0.01% | 94,142 | 58,588 | 164.79% | $28.06 |
| Q1 2023 | Stock | $2,236,000 | < 0.01% | 68,869 | -25,273 | -26.85% | $32.47 |
| Q2 2023 | Stock | $3,039,000 | < 0.01% | 100,309 | 31,440 | 45.65% | $30.30 |
| Q3 2023 | Stock | $3,539,000 | < 0.01% | 129,981 | 29,672 | 29.58% | $27.23 |
| Q4 2023 | Stock | $8,498,000 | < 0.01% | 257,299 | 127,318 | 97.95% | $33.03 |
| Q1 2024 | Stock | $4,905,000 | < 0.01% | 149,626 | -107,673 | -41.85% | $32.78 |
| Q2 2024 | Stock | $1,861,000 | < 0.01% | 97,331 | -52,295 | -34.95% | $19.12 |
| Q4 2024 | Stock | $10,298,000 | < 0.01% | 915,422 | 641,646 | 234.37% | $11.25 |
| Q1 2025 | Stock | $10,262,000 | < 0.01% | 1,083,637 | 168,215 | 18.38% | $9.47 |